28036-91-1

Basic information

• Product Name: 3,4-DICHLOROBENZENE-1-CARBOHYDRAZIDE
• Synonyms: BUTTPARK 35\03-79;3,4-DICHLOROBENZHYDRAZIDE;3,4-DICHLOROBENZENE-1-CARBOHYDRAZIDE;3,4-DICHLOROBENZENECARBOHYDRAZIDE;3,4-Dichlorobenzohydrazide 97%;3,4-DICHLOROBENZOHYDRAZIDE;3,4-Dichlorobenzoic acid hydrazide 97%;3,4-Dichlorobenzhydrazide97%
• CAS NO: 28036-91-1
• Molecular Formula: C₇H₆Cl₂N₂O
• Molecular Weight: 205.04
• Product Categories: Aromatic Hydrazides, Hydrazines, Hydrazones and Oximes
• Mol File: 28036-91-1.mol
• Article Data: 22

Chemical Properties

• Melting Point: 154 °C
• Appearance: /
• Density: 1.455 g/cm³
• Refractive Index: 1.605
• PKA: 11.30±0.10(Predicted)
• CAS DataBase Reference: 3,4-DICHLOROBENZENE-1-CARBOHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DICHLOROBENZENE-1-CARBOHYDRAZIDE(28036-91-1)
• EPA Substance Registry System: 3,4-DICHLOROBENZENE-1-CARBOHYDRAZIDE(28036-91-1)

Safety Data

• Hazard Codes: Xi
• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S37/39:Wear suitable g
• HazardClass: IRRITANT
• Hazardous Substances Data: 28036-91-1(Hazardous Substances Data)

Usage

General Description

3,4-Dichlorobenzene-1-carbohydrazide, also known as 3,4-DCBH, is a chemical compound primarily used as a precursor in the production of dyes and pharmaceuticals. It is a white crystalline solid with a melting point of about 218-221 °C. 3,4-DCBH has been used as a reducing agent in organic synthesis and as an intermediate in the production of pesticides. It is also being investigated for its potential as a corrosion inhibitor in metal industries. However, 3,4-DCBH has been identified as a potential mutagen and is classified as a hazardous substance, so it should be handled with caution and its use should be carefully regulated.

InChI:InChI=1/C7H6Cl2N2O/c8-5-2-1-4(3-6(5)9)7(12)11-10/h1-3H,10H2,(H,11,12)

Upstream product

• 3024-72-4 3,4-dichlorobenzoyl chloride 
• 60-29-7 diethyl ether 
• 28394-58-3 3,4-dichloro-benzoic acid ethyl ester 
• 51-44-5 3,4-dichlorbenzoic acid 
• 2905-68-2 methyl 3,4-dichlorobenzoate 

Downstream Products

• 198067-28-6 N-(3,4-dichlorobenzoyl)-N'-(phenylsulfonyl)hydrazine 
• 380639-32-7 dimethyl (3,4-dichlorobenzoyl)carbonohydrazonodithioate 
• 1456614-10-0 C₁₂H₁₁Cl₂N₅O₂S 
• 1456613-88-9 2-(3,4-dichlorophenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one 
• 1358054-11-1 3-acetyl-5-(3,4-dichloro-phenyl)-2-(5-nitrofuran-2-yl)-2,3-dihydro-1,3,4-oxadiazole 
• 329024-18-2 3,4-dichloro-N’-((5-nitrofuran-2-yl)methylene)benzohydrazide 
• 28004-64-0 5-(3,4-dichloro-phenyl)-[1,3,4]thiadiazol-2-ylamine 
• 28036-92-2 N₂-(3,4-dichlorobenzoyl)thiosemicarbazide 

Relevant articles and documents

Some Novel Mannich Bases of 5-(3,4-Dichlorophenyl)-1,3,4-oxadiazole-2(3H)-one and Their Anti-Inflammatory Activity

Non-steroidal anti-inflammatory drugs (NSAIDs), which are widely used for the treatment of rheumatic arthritis, pain, and many different types of inflammatory disorders, cause serious gastrointestinal (GI) side effects. The free carboxylic acid group exis

Discovery of highly potent tubulin polymerization inhibitors: Design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines

By removing 5-methyl and 6-acetyl groups in our previously reported compound 3, we designed a series of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidine derivatives as potential tubulin polymerization inhibitors. Among them, compound 5e displayed low nanomolar antiproliferative efficacy on HeLa cells which was 166-fold higher than the lead analogue 3. Interestingly, 5e displayed significant selectivity in inhibiting cancer cells over HEK-293 (normal human embryonic kidney cells). In addition, 5e dose-dependently arrested HeLa in G2/M phase through the alterations of the expression levels of p-cdc2 and cyclin B1, and caused HeLa cells apoptosis by regulation of expressions of cleaved PARP. Further evidence demonstrated that 5e effectively inhibited tubulin polymerization and was 3-fold more powerful than positive control CA-4. Moreover, molecular docking analysis indicated that 5e overlapped well with CA-4 in the colchicine-binding site. These studies demonstrated that 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidine skeleton might be used as the leading unit to develop novel tubulin polymerization inhibitors as potential anticancer agents.

NOVEL FUNCTIONALIZED PURINE-2,6-DIONES AND THEIR USE IN MEDICINE

There is provided compounds of formula (I), or pharmaceutically-acceptable salts thereof, wherein R1 to R4 and X1 to X5 have meanings provided in the description, which compounds are useful in the treatment of c